Sclerostin Inhibition in the Management of Osteoporosis.
Sclerostin Inhibition in the Management of Osteoporosis.
复制标题
DOI：
10.1007/s00223-016-0126-6
复制
发表时间：
2016-04
影响因子：
4.2
通讯作者：
Papapoulos SE
中科院分区：
文献类型：
--
作者：
Appelman-Dijkstra NM;Papapoulos SE
随着对Wnt信号通路在骨代谢中重要性的认识，以及对以高骨量为特征的罕见骨骼疾病患者的研究，硬化素被确定为骨质疏松症新疗法的开发靶点。对患有硬化素缺乏症的动物和人类的发现，以及对硬化素抑制剂的临床前和早期临床研究结果表明，一种使用骨生成剂治疗骨质疏松症患者的新治疗范例，其抗骨折效果和长期耐受性仍有待正在进行的第三阶段临床研究中确定。在这篇文章中，我们回顾了目前可用的临床前和临床证据，支持使用硬化素抑制剂治疗骨质疏松症。
The recognition of the importance of the Wnt-signaling pathway in bone metabolism and studies of patients with rare skeletal disorders characterized by high bone mass identified sclerostin as target for the development of new therapeutics for osteoporosis. Findings in animals and humans with sclerostin deficiency as well as results of preclinical and early clinical studies with sclerostin inhibitors demonstrated a new treatment paradigm with a bone building agent for the management of patients with osteoporosis, the antifracture efficacy, and long-term tolerability of which remain to be established in on-going phase III clinical studies. In this article we review the currently available preclinical and clinical evidence supporting the use of sclerostin inhibitors in osteoporosis.